Oura’s Postponement Casts Shadow on IPO Market
Despite being a reported multiple-times oversubscribed from our sources, Oura’s (OURA US) planned IPO has been put on hold, with the company citing market conditions. OURA initially targeted a sale of 50 million shares at $40-$44. Market conditions and an aggressive step-up round into the IPO are both contributing factors for the deal being shelved.
The company was seeking a meaningful increase from its approximately $11 billion valuation in its October 2025 Series E financing, with a fully diluted valuation of roughly $15.6 billion at the top of the proposed IPO range.
The proposed offering represented a substantial test of investor appetite for a consumer-health platform combining hardware, recurring subscriptions and biometric data. Although demand was reportedly strong, the valuation left investors weighing Oura’s growth trajectory against its current profitability and the execution required to achieve longer-term margin targets. One of our sources stated that the company “may” have been willing to price well below the prevailing $40-$44 range however buyers were “balking” at any price.
Oura joins a growing list of companies that have marketed their IPOs only to ultimately postpone their offering prior to pricing. Others that have been shelved in 2026 include Bamboo Insurance Services, Holtec Nuclear Corporation, Copper Tech Metals, and Clear Street Group.
Accelevation Holdings Corp. (ACCV): AI Infrastructure IPO Stays Grounded After Pricing Below Range
Accelevation Holdings (ACCV US) delivered a muted debut Wednesday, with the data center infrastructure company forced to price its full-size IPO below its marketed range before trading in a remarkably tight band throughout the session. ACCV priced 30.0 million shares at $18.00, $2 below the $20-$24 range, and opened at $17.55, a 2.5% discount to the IPO price. The shares briefly moved above the IPO price within the first 15 minutes, reaching a session high of $18.10, before settling at $17.95, essentially flat with the IPO price.
The need to price the offering below the marketed range is the most notable feature of the debut. Accelevation had been targeting a valuation of as much as $5.4 billion based on its original range, but ultimately accepted a lower price to get the transaction across the finish line.
The subdued pricing comes despite a strong fundamental growth story. Accelevation has positioned itself as an integrated provider of power distribution and white-space infrastructure for hyperscale, AI and other data center customers, with revenue growing rapidly alongside the broader AI infrastructure buildout.
The timing also worked against Accelevation. Earlier in the week, Oura’s planned IPO was postponed, adding to questions surrounding the strength of the broader equity capital markets and investors’ willingness to establish valuations for high-growth companies.
The backdrop is particularly relevant for AI infrastructure, where expectations for future growth are high but valuations can vary considerably depending on a company’s position in the supply chain, customer concentration, margins and capital requirements. Higher interest rates also remain a consideration, as elevated rates can place greater pressure on the valuation of long-duration growth companies. With the U.S. midterm elections approaching, broader macroeconomic and policy uncertainty may also be contributing to investor caution.
Accelevation traded as low as $15.03 during Friday’s session before closing the week at $17.72.
The IPO schedule for next week is currently empty, however, there are a handful of biotech offerings that could launch and debut in the same week. TRex Bio Inc., Retention Pharmaceuticals Inc., Iambic Therapeutics Inc., and City Therapeutics Inc are all candidates to come to market in the month of October from the biotech sector.